SCHEMBL1996492

SCHEMBL1996492

Fc1cc(F)cc(Nc2nc3ccccc3[nH]2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
NPC1 O15118 9/20 0.59
RAB9A P51151 9/20 0.59
MTOR P42345 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 3/20 0.55
AKR1C3 P42330 1/20 0.55
GAA P10253 3/20 0.53
ALOX15 P16050 2/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
DDX3X O00571 1/20 0.52
TP53 P04637 4/20 0.50
PKM P14618 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PDE10A Q9Y233 1/20 0.49
LMNA P02545 2/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004629 0.87 MEN1 (0.51) MEN1KMT2ANPC1RAB9AMTOR
SCHEMBL1996591 0.85 MEN1 (0.71) MEN1KMT2ANPC1RAB9AMTOR
SCHEMBL1999412 0.81 MEN1 (0.61) MEN1KMT2ANPC1RAB9AMTOR
SCHEMBL239690 0.81 MEN1 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL30020996 0.81 MEN1 (0.75) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2004452 0.81 MEN1 (0.60) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL28050241 0.80 RAB9A (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1163657 0.80 MEN1 (0.56) MEN1KMT2ANPC1RAB9AMTOR
SCHEMBL30289854 0.79 KDM4E (0.71) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL28728369 0.79 RAB9A (0.66) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US claimed
US-7960561-B2 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2011-06-14 US disclosed
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels NEUROSEARCH A/S (DK) 2009-03-19 US disclosed
EP-1896427-A2 NOVEL 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NeuroSearch A/S (DK) 2008-03-12 EP disclosed
WO-2006136580-A2 2-(PHENYLAMINO)BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076106-A1 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels KCNN2, KCNN1, KCNN3 MEN1 2186/4885KMT2A 1406/4885NPC1 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.